872
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Phosphate binders in chronic kidney disease. When should we start, what should we prescribe?

, MD MSc PhD
Pages 2255-2256 | Published online: 09 Oct 2012

Bibliography

  • Claudius Galenus. De Urinis ex Hippocrate, Galeno et aliis quibusdam. In: De urinis compendium. p. 609-23; 129
  • Cozzolino M, Bruschetta E, Cusi D, Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate. Expert Opin Pharmacother 2012;13(16):2337-2353
  • United States Renal Data System. Annual Data Report Chapter three. In: Morbidity & mortality in patients with chronic kidney disease. Atla of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Istitutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, 2012. p. 59-68
  • Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;290(13):697-701
  • Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5 Suppl 3):S112-19
  • Weiner DE, Tabatabai S, Tighiouart H, Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis 2006;48(3):392-401
  • Vichow R. Kall metastasen. Virchows Arch Pathol 1855;8:103-13
  • Cozzolino M, Gallieni M, Galassi A, Phosphate overload accelerates vascular aging in uremic patients. Heart Int 2006;2(1):6
  • Goodman WG, Goldin J, Kuizon BD, Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342(20):1478-83
  • Navaneethan SD, Palmer SC, Craig JC, Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009;54(4):619-37
  • Block GA, Wheeler DC, Persky MS, Effects of Phosphate Binders in Moderate CKD. J Am Soc Nephrol 2012;23(8):1407-15
  • Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15(7):1014-21
  • KDIGO. Treatment of CKD-MBD targeted at lowering high serum phosphorus and maintaining serum calcium. Kidney Int 2009;76(Suppl 113):S50-9
  • Di IB, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. ClinJ Am Soc Nephrol 2012;7(3):487-93
  • Daugirdas JT, Finn WF, Emmett M, Chertow GM. The phosphate binder equivalent dose. Semin Dial 2011;24(1):41-9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.